Elan Prialt On Track For Q4 Approval; NDA To Seek Acute & Chronic Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Elan plans to focus the launch of its non-opioid analgesic Prialt on cancer, AIDS and neuropathic pain before expanding to broader populations.